Last $8.75 USD
Change Today +0.15 / 1.74%
Volume 228.4K
XNPT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 11:52 AM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

xenoport inc (XNPT) Key Developments

Xenoport, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Xenoport, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, total revenues were $31.068 million against $2.527 million a year ago. Income from operations was $8.312 million loss from operation of against $18.753 million a year ago. Net income was $8.259 million or $0.13 per basic and diluted share against net loss of $18.816 million or $0.39 per basic and diluted share a year ago. For the nine months, total revenues were $39.777 million against $5.072 million a year ago. Loss from operations was $31.504 million $66.569 million a year ago. Net loss was $31.676 million or $0.52 per basic and diluted share against $6.745 million or $1.41 per basic and diluted share a year ago. The increases in Revenues were also due to increased HORIZANT net product sales.

Xenoport, Inc. to Report Q3, 2014 Results on Nov 04, 2014

Xenoport, Inc. announced that they will report Q3, 2014 results at 5:00 PM, US Eastern Standard Time on Nov 04, 2014

Xenoport, Inc., Q3 2014 Earnings Call, Nov 04, 2014

Xenoport, Inc., Q3 2014 Earnings Call, Nov 04, 2014

Xenoport, Inc. Presents at Credit Suisse Annual Healthcare Conference, Nov-12-2014 09:30 AM

Xenoport, Inc. Presents at Credit Suisse Annual Healthcare Conference, Nov-12-2014 09:30 AM. Venue: The Biltmore, 2400 E Missouri Ave, Phoenix, AZ 85016, United States. Speakers: Ronald W. Barrett, Co-Founder, Chief Executive Officer and Director.

XenoPort, Inc. and the National Institute on Alcohol Abuse & Alcoholism Announce Clinical Trial Agreement to Study Horizant as Potential Treatment for Alcohol Use Disorder

XenoPort, Inc. and the National Institute on Alcohol Abuse and Alcoholism announced that they have entered into an agreement to conduct a clinical trial of HORIZANT(R) (gabapentin enacarbil) Extended-Release Tablets as a potential treatment for alcohol use disorder (AUD). Under the terms of the agreement, XenoPort will supply clinical trial material and the NIAAA will conduct and pay all other expenses associated with the proposed clinical trial of HORIZANT. XenoPort will have access to study results generated under the proposed clinical trial to support potential regulatory filings for HORIZANT. The study is planned to be a randomized, double-blind, placebo-controlled clinical trial of the safety and efficacy of HORIZANT in patients who have AUD but are abstinent at treatment initiation. The study is expected to have a treatment period of six months and to enroll approximately 350 patients beginning in the first half of 2015. XenoPort and the NIAAA are planning to meet with the U.S. Food and Drug Administration (FDA) Division of Anesthesia, Analgesia and Addiction Products in the fourth quarter of 2014 to discuss the trial design and the possibility of utilizing the results of this trial as the basis for a potential supplemental new drug application (sNDA) submission for HORIZANT for the maintenance of abstinence from heavy drinking of alcohol in patients with AUD.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XNPT:US $8.75 USD +0.15

XNPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioDelivery Sciences International Inc $13.08 USD +0.37
Depomed Inc $19.16 USD +0.44
Flamel Technologies SA $14.23 USD -0.25
Merrion Pharmaceuticals Plc €0.35 EUR 0.00
PlasmaTech Biopharmaceuticals Inc $3.20 USD +0.06
View Industry Companies
 

Industry Analysis

XNPT

Industry Average

Valuation XNPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.5x
Price/Book 5.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XENOPORT INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.